BYSI BeyondSpring Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1677940 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY7,733.3%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA185.0%
ROIC (approx.)—
Asset turnover0.00x
Leverage & solvency
Liabilities / assets23.2%
Debt / equity0.00x
Current ratio0.28x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-0.35x
Accruals ratio250.5%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| R&D expense | $1.11M | $973,000 | $1.08M | $1.47M | $968,000 | $1.00M | $874,000 | $472,000 |
| SG&A expense | $956,000 | $758,000 | $1.16M | $1.12M | $672,000 | $947,000 | $1.74M | $1.23M |
| Operating income | -$2.06M | -$1.73M | -$2.23M | -$2.60M | -$1.64M | -$1.95M | -$2.61M | -$1.70M |
| Pretax income | -$2.06M | -$1.65M | -$2.16M | -$2.49M | -$1.62M | -$1.86M | -$2.56M | -$1.82M |
| Income tax | $0 | $100,000 | $192,000 | $22,000 | $2,000 | $22,000 | $20,000 | -$96,000 |
| Net income | $50.79M | -$849,000 | -$2.16M | -$2.14M | -$1.54M | -$1.81M | $4.48M | -$1.73M |
| EBITDA | -$2.04M | -$1.71M | -$2.21M | -$2.75M | -$1.56M | -$1.87M | -$2.53M | -$1.68M |
| EPS (basic) | 1.24 | -0.02 | -0.05 | — | -0.04 | -0.04 | 0.11 | — |
| EPS (diluted) | — | — | — | — | — | -0.10 | — | — |
| Balance sheet | ||||||||
| Cash & equivalents | $580,000 | $2.70M | $4.04M | $2.97M | $3.95M | $9.54M | $6.53M | $2.00M |
| Short-term investments | $0 | $3.83M | $3.83M | $1.00M | $141,000 | — | $2.00M | $0 |
| Current assets | $1.28M | $9.90M | $13.50M | $20.88M | $24.41M | $25.71M | $31.53M | $28.58M |
| PP&E, net | $117,000 | $138,000 | $152,000 | $155,000 | $184,000 | $202,000 | $221,000 | $239,000 |
| Total assets | $19.86M | $14.61M | $18.41M | $25.93M | $29.48M | $31.04M | $37.10M | $34.31M |
| Current liabilities | $4.62M | $14.19M | $12.37M | $13.58M | $12.89M | $11.73M | $12.66M | $11.01M |
| Total liabilities | $4.62M | $50.63M | $48.76M | $49.92M | $49.29M | $48.59M | $49.77M | $48.60M |
| Shareholders' equity | $15.24M | -$35.57M | -$34.49M | -$32.16M | -$31.77M | -$30.22M | -$28.31M | -$32.90M |
| Shares outstanding | 41.41M | 41.12M | 41.12M | 41.12M | 41.12M | 40.32M | 40.32M | 40.32M |
| Cash flow statement | ||||||||
| Operating cash flow | -$3.60M | -$3.77M | -$3.28M | -$5.50M | -$4.19M | -$5.87M | -$4.20M | $982,000 |
| Capital expenditure | $2,000 | $0 | $0 | $0 | $0 | $0 | $50,000 | $27,000 |
| Free cash flow | -$3.60M | -$3.77M | -$3.28M | -$5.50M | -$4.19M | -$5.87M | -$4.25M | $955,000 |
| Investing cash flow | $295,000 | -$5,000 | $4.48M | -$5.15M | -$1.22M | $10.85M | $6.30M | -$9.81M |
| Financing cash flow | $8.33M | -$74,000 | -$4.16M | $1.97M | $3.00M | $0 | $0 | $1.84M |
| Depreciation & amortization | $18,000 | $19,000 | $19,000 | -$156,000 | $81,000 | $82,000 | $80,000 | $20,000 |
| Stock-based compensation | $471,000 | $575,000 | $461,000 | $167,000 | $166,000 | $145,000 | $244,000 | $399,000 |
Free plan shows the latest 8 periods; Pro shows all 35 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.